Welcome to our web site!

Our passion for quality and attention to details is evident in the time. The manufacturing and quality are licensed and supervised by Bolise. Bolise Co., Ltd. is biotech laboratories founded in Australia and China in 2001. We focus on research and development of innovative Acridine Raw Material, Pharmaceutical Raw Materials, Pharmaceutical Chemicals.......   >>>Read More

We have satisfied customers from all around the world, including:

You are here: Bolise NewsViews

Sanofi dengue vaccine Dengvaxia re Philippines, Brazil approved


Dengue (Dengue) is an acute dengue virus vector-borne diseases caused by mosquito-borne. Clinical manifestations of high fever, headache, muscle, bone and joint severe pain, rashes, bleeding tendency, swollen lymph nodes, white blood cell count, thrombocytopenia, etc., dengue fever is one of the main reasons of death among children in Southeast Asia.


Dengue fever is a mosquito-borne disease, commonly known as "hot broken bones (breakbone fever)", a threat to nearly three billion people, the epidemic in Asia and Latin America. According to the World Health Organization (WHO) is expected to have over 100 million people infected with dengue each year. Dengue fever is often mild nonspecific due to a wide range of life-threatening complications of clinical symptoms and misdiagnosis, but the limitations of the monitoring system also causes dengue cases reported insufficient. Worldwide, there are 50 million people (including children) suffer from dengue hemorrhagic fever (DHF), timely access to appropriate health care is crucial to reducing the risk of severe dengue deaths annually.


WHO has set a target that by 2020, the dengue mortality by 50 percent, reduce the incidence of 25%. Currently, dengue hemorrhagic fever yet have any specific treatments. Dengue by the four different serotypes of dengue virus initiator, no immunity among strains, it can be a different dengue virus serotypes superinfection.


Following last December after obtaining the approval of the Mexican, French pharmaceutical giant Sanofi (Sanofi) of its vaccines division Sanofi Pasteur (Sanofi Pasteur) developed dengue vaccine Dengvaxia recently re-Philippines, ratified by Brazil, which also marks the Second, the three vaccines worldwide regulatory approval harvested.


Dengvaxia is the world's first dengue vaccine is approved, the vaccine is a major milestone for global public health community, especially about half live in dengue risk in the global population, is a historic.


Dengvaxia apply to live in dengue endemic areas 9 -45 years old children, adolescents and adults, for the prevention of all four serotypes of the dengue virus caused disease. Dengvaxia approved, is based on an extensive clinical development program, the project involves more than 40,000 volunteers who live in 15 countries, and have different ages, geographic area, epidemiology, ethnicity, socio-economic background. Clinical data show, Dengvaxia reduces all four serotypes of dengue virus infection risk in two-thirds of the subjects, while 80% of the dengue prevention of hospitalization and up to 93% of severe dengue cases.


In Asia, about 67 million people infected with dengue each year, the region accounts for about 70% of the global burden of dengue. It is estimated that, in endemic countries in Asia, the direct and indirect medical expenses caused by the dengue epidemic up to $ 6.5 billion annually. Dengvaxia as Asia's first dengue vaccine, the disease will be a serious threat to human health aspects play an important role in the prevention of this.